IP Library Granted Patent US 8,603,541
Granted Patent B2
US 8,603,541 · App. 13/331,309 · Granted Dec 10, 2013

Viral inactivated platelet extract, use and preparation thereof

Inventors: Lior Weissman (Nes-Ziona, IL); Nina Raver-Shapira (Ramot Meir, IL); Israel Nur (Moshav Timmorim, IL); Oleg Belyaev (Petah Tikva, IL)
Assignee: Omrix Biopharmaceuticals Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,541
App. No.
13/331,309
Granted
Dec 10, 2013
Kind
B2
Abstract

The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Claims (28)

1. A method for preparing a viral-safe platelet extract comprising trophic factors and/or growth factors, the method comprising at least two orthogonal viral inactivation treatments and comprising the following steps:

(a) providing a platelet-enriched fraction comprising trophic factors and/or growth factors from multiple donors;

(b) preparing a platelet lysate from the platelet enriched fraction in (a);

(c) carrying out a solvent-detergent (S/D) viral inactivation treatment of the resultant lysate from step (b);

(d) removing the S/D from the resultant viral inactivated platelet lysate of step (c) by hydrophobic interaction chromatography (HIC), wherein the HIC comprises the steps of: loading the resultant lysate from step (c) to HIC resin, and collecting a material eluted under non isocratic conditions from the HIC resin; and conducting a second orthogonal viral inactivation treatment on said eluted material to obtain the viral-safe platelet extract comprising growth factors and/or trophic factors.

2. The method according to claim 1 , wherein preparing the platelet lysate is carried out during the S/D viral inactivation treatment.

3. The method according to claim 1 , wherein during the S/D viral inactivation treatment a step of aggregate reduction is carried out.

4. The method according to claim 3 , wherein the aggregate reduction is carried out by filtration.

5. The method according to claim 1 , wherein the HIC of step (d) comprises the steps of:

(d1) loading the platelet lysate on a HIC resin;

(d2) washing the resultant loaded HIC resin from (d1) with an isocratic solution;

(d3) collecting the unbound material;

(d4) washing the HIC resin from step (d3) with a non isocratic solution; and,

(d5) collecting the eluted material.

6. The method according to claim 5 , wherein the isocratic solution consists of acetate glycine buffer and human serum albumin; and wherein the non isocratic solution comprises an organic solvent and/or a molecule capable of binding platelet derived factors.

7. The method according to claim 1 , further comprising contacting the resultant lysate from steps (b) and/or (c) with a molecule capable of binding platelet-derived factors prior to S/D removal.

8. The method according to claim 6 or 7 , wherein the molecule is selected from the group consisting of heparin, dextran sulphate and combination thereof.

9. The method according to claim 1 , wherein the second orthogonal viral inactivation treatment comprises heat inactivation.

10. The method according to claim 1 , wherein the platelet-enriched fraction is a washed and/or leukocyte-reduced platelet fraction from aphaeresis pooled from multiple donors prior to step (b).

11. The method according to claim 1 , further comprising lyophilizing the resultant viral-safe extract from step (d).

12. A method for removing solvent-detergent (S/D) from a biological liquid preparation by HIC, comprising the steps of:

(a) providing the biological liquid preparation;

(b) loading the biological liquid preparation from (a) onto the HIC resin; and

(c) collecting a material eluted from the resultant loaded HIC resin from (b) under non isocratic conditions, wherein the biological liquid preparation is a platelet extract derived preparation comprising trophic factors and/or growth factors.

13. The method according to claim 12 , wherein the method step (b) comprises the steps of:

(b1) washing the loaded HIC resin with an isocratic solution; and

(b2) collecting the unbound material.

14. The method according to claim 13 , wherein the isocratic solution consists of acetate glycine buffer and human serum albumin; and wherein the non isocratic solution comprises an organic solvent and/or a molecule capable of binding platelet derived factors.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2012
From: WEISSMAN, LIOR; RAVER-SHAPIRA, NINA; NUR, ISRAEL; BELYAEV, OLEG
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 027655/0277 →
Priority Claims (1)
IL 210162 · Dec 21, 2010 · national
Continuity (2)
Provisional Application 61425474 · Dec 21, 2010
Related Publication 20120156306A1 · Jun 21, 2012